Endocrine-related cancer最新文献

Streptozotocin-based chemotherapy in advanced PanNETs: a systematic review and meta-analysis. 基于链脲佐菌素的晚期PanNETs化疗：系统回顾和荟萃分析。

IF 4.6

Endocrine-related cancer Pub Date : 2026-10-19 DOI: 10.1530/ERC-26-0338

Giulia Arrivi, Giuseppe Lamberti, Sara Pusceddu, Riccardo Marconcini, Maria Grazia Maratta, Francesco Panzuto, Davide Campana

{"title":"Streptozotocin-based chemotherapy in advanced PanNETs: a systematic review and meta-analysis.","authors":"Giulia Arrivi, Giuseppe Lamberti, Sara Pusceddu, Riccardo Marconcini, Maria Grazia Maratta, Francesco Panzuto, Davide Campana","doi":"10.1530/ERC-26-0338","DOIUrl":"https://doi.org/10.1530/ERC-26-0338","url":null,"abstract":"Background: Streptozotocin (STZ)-based chemotherapy remains a treatment option for advanced pancreatic neuroendocrine tumours (PanNETs), particularly when tumour shrinkage is a therapeutic priority. However, its activity has been reported across heterogeneous treatment schedules, patient populations, and response-assessment eras. We conducted a systematic review and meta-analysis to estimate objective response rate (ORR) and landmark progression-free survival (PFS).Methods: We systematically reviewed randomised trials, prospective studies, and retrospective cohorts reporting ORR and/or PFS with STZ-containing regimens. Random-effects meta-analyses were conducted in a primary ELIGIBLE dataset restricted to advanced or metastatic pancreatic-only cohorts with standardised outcome assessment, and in a broader ALL dataset for contextual analyses. Comparisons across regimen families were exploratory.Results: Twenty-seven studies including 1,744 patients were included. In the ELIGIBLE dataset, pooled ORR was 36.1% (95% CI 30.6-42.0), with a 95% prediction interval of 23.0-51.0%. Landmark PFS was 59.2% (50.6-67.2) at 12 months and 41.5% (33.4-50.1) at 24 months. Estimates from the ALL dataset were directionally consistent but more heterogeneous. No statistically significant differences were detected between regimen families. Certainty of evidence was very low, mainly because of risk of bias and inconsistency.Conclusion: In cohorts using standardised outcome assessment, STZ-containing regimens were associated with objective responses in approximately one-third of patients, supporting their consideration when tumour shrinkage is a major therapeutic objective. These single-arm pooled estimates do not establish superiority among STZ schedules or relative to other treatments, and the PFS benchmarks require cautious interpretation because of substantial clinical and methodological heterogeneity.","PeriodicalId":93989,"journal":{"name":"Endocrine-related cancer","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149221164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunomodulatory actions of catecholamines, cluster-specific signaling pathways, and metabolites in pheochromocytoma and paraganglioma. 儿茶酚胺、簇特异性信号通路和代谢物在嗜铬细胞瘤和副神经节瘤中的免疫调节作用。

IF 4.6

Endocrine-related cancer Pub Date : 2026-10-15 DOI: 10.1530/ERC-26-0280

Jens A Venema, Joanne M de Laat, Romana T Netea-Maier, Margo Dona, Henri Jlm Timmers

{"title":"Immunomodulatory actions of catecholamines, cluster-specific signaling pathways, and metabolites in pheochromocytoma and paraganglioma.","authors":"Jens A Venema, Joanne M de Laat, Romana T Netea-Maier, Margo Dona, Henri Jlm Timmers","doi":"10.1530/ERC-26-0280","DOIUrl":"https://doi.org/10.1530/ERC-26-0280","url":null,"abstract":"Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms with an exceptionally high genetic contribution, often driven by single high-penetrance mutations. Approximately one third of patients harbor germline mutations and another third carry somatic driver mutations, allowing stratification into three molecular clusters: pseudohypoxia-related (cluster 1), kinase signaling-related (cluster 2) and Wnt-signaling-related (cluster 3). These clusters differ in catecholamine secretion, malignancy, and metastatic behavior. Although PPGLs have long been viewed as immunologically 'cold' due to their low neoantigen load and limited T cell infiltration, recent studies show a more complex immune landscape, with differences observed between indolent and metastatic tumors, and between genomic clusters. The interaction between the tumor and immune system is, in general, closely associated with tumorigenesis and disease prognosis, with both the innate and adaptive immune system playing pivotal roles. This review summarizes how tumor-derived catecholamines and cluster-specific genetic drivers and metabolic programs are able to orchestrate immune modulation in PPGL. Within clusters of PPGL, distinct metabolic and signaling alterations such as pseudohypoxia, tricarboxylic acid cycle oncometabolites, and aberrant kinase and B-catenin signaling shape both the tumor microenvironment and systemic immune response. We highlight therapeutic opportunities together with approaches that harness or reprogram innate immune memory. Recognizing PPGL as metabolically and immunologically stratified tumors may enable rational, personalized combination therapies for patients with inoperable, recurrent or metastatic disease, and might explain the heterogeneous response to immunotherapy currently observed.","PeriodicalId":93989,"journal":{"name":"Endocrine-related cancer","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Horizons in Pharmacotherapy for Cushing's Disease and Acromegaly. 库欣病和肢端肥大症药物治疗的新视野。

IF 4.6

Endocrine-related cancer Pub Date : 2026-10-15 DOI: 10.1530/ERC-26-0317

Maria Fleseriu, Shlomo Melmed, Artak Labadzhyan

{"title":"New Horizons in Pharmacotherapy for Cushing's Disease and Acromegaly.","authors":"Maria Fleseriu, Shlomo Melmed, Artak Labadzhyan","doi":"10.1530/ERC-26-0317","DOIUrl":"https://doi.org/10.1530/ERC-26-0317","url":null,"abstract":"The recent development of new medical therapies has transformed Cushing's disease and acromegaly management, offering patients more individualized and effective treatment strategies beyond surgery and also addressing unmet clinical needs for persistent disease. In Cushing's disease, newer steroidogenesis inhibitors, pituitary-directed therapies, and glucocorticoid receptor antagonists coupled with increasing recognition of disease heterogeneity have highlighted the importance of individualized therapy selection based on corticotroph adenoma characteristics, severity of hypercortisolism, comorbidities, and patient-specific priorities. Management strategies increasingly focus on normalization of biochemical markers and on improvement in quality of life and metabolic outcomes, cardiovascular risk reduction, and prolongation of long-term remission. In acromegaly, the medical treatment landscape has expanded beyond monthly injectable and/or oral somatostatin receptor ligands and pegvisomant to include newer octreotide formulations, selective oral somatostatin receptor agonists, combination approaches, and a highly targeted growth hormone receptor antagonist. These developments have enabled improved biochemical control, patient convenience, and long-term disease management. Nevertheless, unmet challenges in enabling optimal management include delayed diagnosis, treatment resistance, adverse drug effects, adenoma recurrence, and the burden of chronic disease monitoring. For both disorders, ongoing clinical trials and emerging precision medicine approaches are refining therapeutic algorithms and offer optimism for further improved patient outcomes. This review focuses on newly approved and investigational medical treatments for acromegaly and Cushing's disease and their evolving role within pituitary care.","PeriodicalId":93989,"journal":{"name":"Endocrine-related cancer","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tyrosine Kinase Inhibitors in Metastatic Pheochromocytomas and Paragangliomas: An Updated Systematic Review and Meta-Analysis. 酪氨酸激酶抑制剂在转移性嗜铬细胞瘤和副神经节瘤中的应用：最新的系统综述和荟萃分析。

IF 4.6

Endocrine-related cancer Pub Date : 2026-10-14 DOI: 10.1530/ERC-26-0201

Xiaowen Xu, Quanheng Liu, Shihui Xu, Awan Hasham Ikram, Herve Pasteur Ndikuriyo, Yizhou Wang, Kai Cheng, Zhi Li, Junjie Chen, Minghao Li, Qiao Xiao, Longfei Liu

{"title":"Tyrosine Kinase Inhibitors in Metastatic Pheochromocytomas and Paragangliomas: An Updated Systematic Review and Meta-Analysis.","authors":"Xiaowen Xu, Quanheng Liu, Shihui Xu, Awan Hasham Ikram, Herve Pasteur Ndikuriyo, Yizhou Wang, Kai Cheng, Zhi Li, Junjie Chen, Minghao Li, Qiao Xiao, Longfei Liu","doi":"10.1530/ERC-26-0201","DOIUrl":"https://doi.org/10.1530/ERC-26-0201","url":null,"abstract":"Therapeutic options for metastatic pheochromocytomas/paragangliomas (mPPGLs) remain limited. Recent studies indicate tyrosine kinase inhibitors (TKIs) offer a promising treatment approach. This study aims to evaluate the efficacy and safety of TKIs for mPPGLs based on available evidence. A systematic search for studies investigating the treatment of TKIs for mPPGL was conducted across PubMed, Embase, and Web of Science from databases inception to February, 2026. Data were synthesized using fixed or random effects meta-analysis model. Subgroup analysis was conducted based on status of SDHB gene and subtypes of TKIs. A total of 11 studies, comprising 4 observational and 7 interventional studies, with 246 patients involved. The stable disease rate, objective response rate (ORR), and disease control rate (DCR) were 51.8%(95% CI, 44.6%-59.1%), 27.7%(95% CI, 21.6%-34.3%), and 84.2%(95% CI, 74.8%-91.9%), respectively. The proportion of discontinuation due to adverse events was 11.3%(95% CI, 5.4%-18.7%). The combined median progression-free survival and overall survival were 13.4 (95% CI, 7.9-14.7) and 26.7(95% CI, 24.9-49.4) months. Pooled ORR(36.8%[95% CI, 21.1%-53.8%] vs. 20.1%[95% CI, 10.8%-31.0%], P=0.06).and DCR (92.2%[95% CI, 79.6%-99.7%] vs. 78.5%[95% CI, 57.3%-94.5%]; P=0.269) were higher in patients with SDHB-related mPPGL than in those with non-SDHB mPPGL, although the differences were not statistically significant. Notably, sunitinib showed no therapeutic superiority over other TKI subtypes, with lower pooled ORR (21.2%[95% CI, 14.0%-29.4%] vs 36.9%[95% CI, 26.9%-47.4%]; P=0.04) and DCR (72.6%[95% CI, 63.9%-80.6%] vs 94.5%[95% CI, 87.2%-99.3%]; P=0.001). Consequently, TKIs show promising efficacy and manageable adverse event rates in mPPGL, supporting TKIs as components of the systematic treatment.","PeriodicalId":93989,"journal":{"name":"Endocrine-related cancer","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Applying 177Lu-Dotatate for Hereditary Neuroendocrine Tumours: The Role in MEN1. 177Lu-Dotatate在遗传性神经内分泌肿瘤中的应用：MEN1的作用。

IF 4.6

Endocrine-related cancer Pub Date : 2026-10-08 DOI: 10.1530/ERC-25-0514

Morticia N Becx, Mark J C van Treijen, Tessa Brabander, Wouter W de Herder, Arthur J A T Braat, Richard A Feelders, Julie Nonnekens, Johannes Hofland

{"title":"Applying 177Lu-Dotatate for Hereditary Neuroendocrine Tumours: The Role in MEN1.","authors":"Morticia N Becx, Mark J C van Treijen, Tessa Brabander, Wouter W de Herder, Arthur J A T Braat, Richard A Feelders, Julie Nonnekens, Johannes Hofland","doi":"10.1530/ERC-25-0514","DOIUrl":"https://doi.org/10.1530/ERC-25-0514","url":null,"abstract":"Introduction: Multiple endocrine neoplasia type 1 (MEN1) is the most common genetic syndrome causing neuroendocrine tumours (NET) with metastatic duodenopancreatic NET (dpNET) forming the predominant cause of MEN1-related mortality. Peptide receptor radionuclide therapy with [177Lu]Lu-[DOTA0,Tyr3]-octreotate (177Lu-Dotatate) is an established treatment for advanced dpNET. As MEN1 loss-of-function has been associated with potential radiosensitising effects, this retrospective study evaluated outcomes of patients with germline MEN1-associated NET after treatment with 177Lu-Dotatate.Methods: This is a retrospective cohort study in patients with MEN1 and metastatic NET treated with 177Lu-Dotatate compared to a control group of patients with advanced sporadic pancreas NET (panNET). Survival outcomes, response rates and adverse events after the initiation of 177Lu-Dotatate were evaluated.Results: A total of nineteen MEN1 patients with dpNET and fifty-seven sporadic panNET controls were included. No significant difference in median progression-free survival with 39.6 months (95%CI 13.7-65.5) in the MEN1 group versus 45.0 months (95%CI 35.7-54.3) in the control group was seen, with a hazard ratio of 1.086 (95%CI 0.60-1.98). Overall survival was similar between groups with 97.8 months (95%CI 36.3-159.3) and 89.3 months (95%CI 54.6-123.9), respectively, and a hazard ratio of 0.883 (95%CI 0.43-1.82). There were no significant differences in objective radiological response (44.4% in the MEN1 group versus 35.2% in the control group) or in grade ≥ 3 toxicity.Conclusion: MEN1 patients with advanced dpNET benefit equally from 177Lu-Dotatate treatment as those with sporadic panNET in terms of survival and response. These findings support the use of PRRT in MEN1-associated dpNET similar to sporadic cases.","PeriodicalId":93989,"journal":{"name":"Endocrine-related cancer","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential for pathogenic protein acylation in succinate dehydrogenase-deficient pheochromocytoma and paraganglioma. 琥珀酸脱氢酶缺陷型嗜铬细胞瘤和副神经节瘤致病性蛋白酰化的可能性。

IF 4.6

Endocrine-related cancer Pub Date : 2026-10-07 DOI: 10.1530/ERC-26-0243

Sherry X Zhou, L James Maher

{"title":"Potential for pathogenic protein acylation in succinate dehydrogenase-deficient pheochromocytoma and paraganglioma.","authors":"Sherry X Zhou, L James Maher","doi":"10.1530/ERC-26-0243","DOIUrl":"https://doi.org/10.1530/ERC-26-0243","url":null,"abstract":"Historically, the study of cellular metabolism and the cellular proteome have largely focused on specific proteins and metabolites in certain cellular pathways. With the advent of new \"omics\" technologies, researchers have been able to probe disruptions and alterations in cellular homeostasis on a near proteome-wide and metabolome-wide basis. Yet the truly interconnected and interdependent nature of the cellular metabolome and proteome has only become more evident with the discovery of proteome-wide protein post-translational modifications (PTMs) such as lysine acylation by acetyl-CoA or succinyl-CoA. Such PTMs link proteome function to fluctuating concentrations of tricarboxylic acid (TCA) cycle metabolites. Tumorigenesis in TCA cycle-defective tumors that upregulate acylating agents such as succinyl-CoA and acetyl-CoA provides a relevant context for understanding the breadth of protein acylation in disease. In particular, succinate dehydrogenase (SDH)-loss chromaffin cells can be transformed to the neuroendocrine tumors pheochromocytoma and paraganglioma (PPGL), but sensitive diagnostic and effective therapeutic options for metastatic disease remain limited. Interrogating cell models of SDH-loss PPGL provides a unique opportunity to capture the effects of SDH loss on cellular metabolism and protein acylation while exploring new avenues for improved diagnostics and novel therapeutic targets in these rare diseases.","PeriodicalId":93989,"journal":{"name":"Endocrine-related cancer","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MIB2-mediated ubiquitination of HK2 inhibits glycolysis in PTC. mib2介导的HK2泛素化抑制PTC的糖酵解。

IF 4.6

Endocrine-related cancer Pub Date : 2026-10-07 DOI: 10.1530/ERC-26-0049

Lijun Zhang, Houchao Tong, Chengyuan Li, Jianing Zhou, Jingsheng Cai, Haisheng Fang, Jianfei Wen, Xiang Zhang, Heda Zhang, Meiping Shen, Yong Wang, Yan Si

{"title":"MIB2-mediated ubiquitination of HK2 inhibits glycolysis in PTC.","authors":"Lijun Zhang, Houchao Tong, Chengyuan Li, Jianing Zhou, Jingsheng Cai, Haisheng Fang, Jianfei Wen, Xiang Zhang, Heda Zhang, Meiping Shen, Yong Wang, Yan Si","doi":"10.1530/ERC-26-0049","DOIUrl":"https://doi.org/10.1530/ERC-26-0049","url":null,"abstract":"Papillary thyroid carcinoma (PTC), the most common endocrine malignancy, frequently exhibits invasive behaviors including tumor invasion and cervical lymph node metastasis, which serve as major determinants of prognosis. However, reliable predictive biomarkers for these aggressive features remain elusive. This study systematically elucidates the tumor-suppressive role of MIB E3 ubiquitin protein ligase 2 (MIB2) in PTC and delineates its underlying molecular mechanism. Integrated bioinformatics analysis and validation in clinical specimens demonstrated significant downregulation of MIB2 in PTC tissues relative to normal thyroid counterparts, with reduced MIB2 expression strongly inversely correlated with aggressive clinicopathological parameters, including lymph node metastasis and extrathyroidal extension. Functional assays revealed that ectopic MIB2 expression markedly attenuated PTC cell proliferation, migration, and invasion in vitro and tumorigenicity in vivo, whereas MIB2 knockdown exacerbated these malignant phenotypes. Mechanistically, MIB2 directly interacted with hexokinase 2 (HK2) via its RING domain, thereby promoting K48-linked polyubiquitination and subsequent proteasomal degradation of HK2. This led to substantial suppression of HK2 protein levels, impairment of glycolytic flux, and consequent restriction of PTC cell aggressiveness. To our knowledge, this is the first demonstration that MIB2 functions as a key negative regulator of PTC invasiveness by targeting HK2 for K48-linked ubiquitination-dependent degradation, thereby modulating glycolytic metabolism. These findings establish MIB2 as a critical suppressor in PTC progression and highlight its potential as a diagnostic biomarker and therapeutic target for aggressive PTC, providing a foundation for the development of precision intervention strategies.","PeriodicalId":93989,"journal":{"name":"Endocrine-related cancer","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer-Associated Fibroblasts Drive Papillary Thyroid Cancer Progression through ROS/NF-κB/IL-6 Signaling in Hypoxic Microenvironment. 癌症相关成纤维细胞通过缺氧微环境下ROS/NF-κB/IL-6信号驱动甲状腺乳头状癌进展

IF 4.6

Endocrine-related cancer Pub Date : 2026-10-07 DOI: 10.1530/ERC-26-0198

Hongjun Song, Xianzhao Deng, Chentian Shen, Yang Wang, Chuang Xi, Yunyun Zhu, Jian Wang, Quanyong Luo, Zhongling Qiu

{"title":"Cancer-Associated Fibroblasts Drive Papillary Thyroid Cancer Progression through ROS/NF-κB/IL-6 Signaling in Hypoxic Microenvironment.","authors":"Hongjun Song, Xianzhao Deng, Chentian Shen, Yang Wang, Chuang Xi, Yunyun Zhu, Jian Wang, Quanyong Luo, Zhongling Qiu","doi":"10.1530/ERC-26-0198","DOIUrl":"https://doi.org/10.1530/ERC-26-0198","url":null,"abstract":"Cancer-associated fibroblasts (CAFs) are key components of the tumour microenvironment (TME) in papillary thyroid carcinoma (PTC) and play a critical role in disease progression. We previously reported that interleukin-6 (IL-6) promotes PTC progression through activation of MAPK signalling. However, whether CAFs serve as a major source of IL-6 and the underlying regulatory mechanisms remain incompletely understood. By integrating single-cell RNA-seq data from PTC patients, we identified fibroblasts as the predominant cellular source of IL-6, with IL-6 expression positively correlated with the CAF marker ACTA2. Primary CAFs isolated from PTC tissues exhibited enhanced proliferation, migration, glycolysis and IL-6 secretion compared with normal fibroblasts (NFs), and these phenotypes were further potentiated by hypoxia. Mechanistically, hypoxia induced reactive oxygen species (ROS) accumulation in CAFs, which activated NF-κB signalling to drive IL-6 production. Blocking NF-κB with JSH-23 or scavenging ROS with NAC or MitoQ abrogated hypoxia-induced IL-6 expression. In non-contact co-cultures, CAF-derived IL-6 promoted PTC cell proliferation and MAPK pathway activation under hypoxia, whereas IL-6 knockdown reversed these effects. In vivo, co-injection of CAFs with PTC cells enhanced tumour growth, which was significantly suppressed by the IL-6 receptor blocker tocilizumab. Collectively, these findings reveal that hypoxia activates a ROS/NF-κB/IL-6 axis in CAFs, which in turn drives PTC progression through paracrine IL-6 signalling. Targeting this pathway may represent a potential therapeutic strategy for aggressive PTC.","PeriodicalId":93989,"journal":{"name":"Endocrine-related cancer","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk factors for subsequent thyroid neoplasms development in childhood cancer survivors. 儿童癌症幸存者甲状腺肿瘤发展的危险因素。

IF 4.6

Endocrine-related cancer Pub Date : 2026-10-05 DOI: 10.1530/ERC-26-0210

Dana Nováková, Karel Švojgr, Rami Katra, Tereza Bartůňková, Petr Vlček, Anna Kindlová, Michaela Jirkovská, Sarah Blagodárna, Tomáš Eckschlager, Lucie Šrámková, Jarmila Kruseová

{"title":"Risk factors for subsequent thyroid neoplasms development in childhood cancer survivors.","authors":"Dana Nováková, Karel Švojgr, Rami Katra, Tereza Bartůňková, Petr Vlček, Anna Kindlová, Michaela Jirkovská, Sarah Blagodárna, Tomáš Eckschlager, Lucie Šrámková, Jarmila Kruseová","doi":"10.1530/ERC-26-0210","DOIUrl":"https://doi.org/10.1530/ERC-26-0210","url":null,"abstract":"Subsequent thyroid carcinomas (STC) are common after childhood cancer treatment and have well-described risk factors, whereas information on subsequent thyroid adenomas (STA) remains limited. This study compared treatment-related risk factors for STC and STA, assessed their associations with the other subsequent neoplasms and evaluated the incidence of STC relative to the age-matched national general population. The study cohort included 4348 childhood cancer survivors treated between 1975 and 2020; 48% were female, 23% had lymphomas and 77% had solid tumors. STC occurred in 44 survivors (59% female) and STA in 23 (65% female). Compared with the national general population, the risk of STC was 7.6-fold higher in females and 23.6-fold higher in males. The median age at diagnosis was lower for STC (25.8 vs. 29.8 years). Hodgkin lymphoma was the most frequent primary cancer (48% vs. 57%). The median age at first cancer diagnosis was similar (9.8 vs. 9.4 years). Neck radiotherapy was a major risk factor in both groups (59% vs. 83%). Additional subsequent malignant neoplasms occurred in 14% of STC patients and 13% of STA patients, while subsequent benign neoplasms occurred in 20% and 26%, respectively. The incidence of subsequent benign neoplasms was higher in STC patients compared to other first subsequent malignant neoplasm patients (p<0.05). STC predominated over STA (66%). Shared risk factors included neck radiotherapy and Hodgkin lymphoma. STC was diagnosed at a younger age. The frequent occurrence of additional subsequent neoplasms highlights the need for long-term surveillance.","PeriodicalId":93989,"journal":{"name":"Endocrine-related cancer","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149120701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Parathyroid carcinoma and primary hyperparathyroidism: trends and outcomes. 甲状旁腺癌和原发性甲状旁腺功能亢进：趋势和结果。

IF 4.6

Endocrine-related cancer Pub Date : 2026-10-01 DOI: 10.1530/ERC-26-0259

Seungjin Baek, Min Heui Yu, Dong Wook Kim, Chang Gon Kim, Na-Young Shin, Milim Kim, Yumie Rhee, Jong Ju Jeong, Namki Hong

{"title":"Parathyroid carcinoma and primary hyperparathyroidism: trends and outcomes.","authors":"Seungjin Baek, Min Heui Yu, Dong Wook Kim, Chang Gon Kim, Na-Young Shin, Milim Kim, Yumie Rhee, Jong Ju Jeong, Namki Hong","doi":"10.1530/ERC-26-0259","DOIUrl":"10.1530/ERC-26-0259","url":null,"abstract":"Parathyroid carcinoma is rare, and its epidemiological relationship to non-cancer primary hyperparathyroidism, along with the comparative long-term cardiometabolic burden of both conditions, remains poorly characterized at the population level. Using the Korea National Health Insurance Service database (2005-2020), we identified 296 patients with incident parathyroid carcinoma and 6,837 patients with non-cancer primary hyperparathyroidism, compared against 71,330 age- and sex-matched controls from the general population. Over the study period, the annual incidence of non-cancer primary hyperparathyroidism increased 7.7-fold, while that of parathyroid carcinoma rose 5.0-fold; because benign disease expanded more rapidly, the proportional contribution of carcinoma among all primary hyperparathyroidism cases declined from 6.67% (2006-2010) to 4.06% (2016-2020). Survival analysis demonstrated that both parathyroid carcinoma (adjusted hazard ratio: 2.29; 95% confidence interval: 1.53-3.43) and non-cancer primary hyperparathyroidism (adjusted hazard ratio: 1.22; 95% confidence interval: 1.09-1.35) were associated with significantly higher 10-year all-cause mortality than matched controls, with mortality risk markedly greater in the carcinoma group. Both parathyroid conditions also conferred modestly elevated risks of subsequent incident cardiometabolic complications, including atherosclerotic cardiovascular disease and new-onset type 2 diabetes mellitus. These findings document a rising burden of parathyroid disease in Korea and underscore the need for cardiometabolic risk surveillance in patients with both malignant and benign parathyroid disorders.","PeriodicalId":93989,"journal":{"name":"Endocrine-related cancer","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0